Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Company Overview - Annexon, Inc. is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [1][3] - The company targets C1q, a key molecule in the classical complement pathway, to prevent tissue damage and neuroinflammation [3] Clinical Development - Annexon is advancing a late-stage clinical platform with investigational drug candidates aimed at addressing the unmet needs of over 8 million people globally suffering from serious neuroinflammatory diseases [3] Upcoming Events - Douglas Love, the president and CEO of Annexon, will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. EST [1] - A live webcast of the presentation will be available on the company's Investors page, with a replay accessible for 30 days post-event [2]